scholarly journals PostCOVID effect on endothelial function in hypertensive patients: A new research opportunity

2021 ◽  
Author(s):  
Luis Giménez‐Miranda ◽  
Luis Beltrán‐Romero ◽  
David León‐Jimenez ◽  
Pablo Stiefel
Keyword(s):  
Endothelial Function ◽  
Hypertensive Patients ◽  
Research Opportunity ◽  
New Research

Beneficial effect of azilsartan and amlodipine on endothelial function in hypertensive patients

2016 ◽  
Vol 252 ◽  
pp. e53 ◽  
Author(s):  
T. Nishida ◽  
M. Ayaori ◽  
K. Shiotani ◽  
H. Uto-Kondo ◽  
M. Sasaki ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Beneficial Effect ◽  
Hypertensive Patients

Endothelial Function in Diabetic Hypertensive Patients

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154636
Author(s):  
M. Derevyanchenko ◽  
M. Statsenko
Keyword(s):  
Endothelial Function ◽  
Hypertensive Patients

scholarly journals Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study

2019 ◽  
Vol 20 (3) ◽  
pp. 147032031986889 ◽  
Author(s):  
Piotr Ruszkowski ◽  
Anna Masajtis-Zagajewska ◽  
Michał Nowicki
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Angiotensin Converting Enzyme ◽  
Endothelial Function ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Reactive Protein

Background: The aim of this study was to compare the influence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on endothelial function and blood pressure in patients with essential hypertension on long-term angiotensin-converting enzyme inhibitor therapy. Method: The study was designed as a prospective, double-blind, randomised, placebo controlled, crossover clinical trial. Twenty patients with essential hypertension were treated with an angiotensin-converting enzyme inhibitor; the control group included 10 healthy subjects. Hypertensive patients received in random order 80 mg of fluvastatin daily or placebo for 6 weeks. The following parameters were assessed at baseline and after each treatment period: serum lipids, flow-mediated vasodilation, activity of von Willebrand factor, concentration of vascular endothelial growth factor, C-reactive protein and 24-hour blood pressure profile. Results: Hypertensive patients did not differ from healthy subjects with respect to age, body mass and biochemical parameters, with the exception of C-reactive protein, which was higher in hypertensive patients ( P=0.02). After statin therapy, low-density lipoprotein cholesterol ( P<0.0001), C-reactive protein ( P=0.03), von Willebrand factor ( P=0.03) and vascular endothelial growth factor ( P<0.01) decreased and flow-mediated vasodilation improved ( P<0.001). Statins had no significant effect on blood pressure. Conclusions: Statins added to angiotensin-converting enzyme inhibitors may improve endothelial function and ameliorate inflammation independently of blood pressure.

Sign in / Sign up

Export Citation Format

Share Document